

## **Review Article**

### **Dermatofibrosarcoma Protuberans: A Systematic Review of The Literature**

#### **Abstract:**

**Background:** *Dermatofibrosarcoma Protuberans (DFSP)* is a rare slow growing cutaneous soft tissue sarcoma, that is characterized to be locally invasive with high recurrence rate. However, it has poor metastatic capacity.

**Objective:** We are conducting this literature review to gather evidence-based medicine knowledge regarding *Dermatofibrosarcoma Protuberans*. Moreover, this study highlights the gaps of knowledge in regard to this disease entity.

**Methods:** The literature search was conducted by searching the keywords "*Dermatofibrosarcoma Protuberans*" and "soft tissue sarcomas" in PubMed and Web of Science databases.

**Results:** 1,769 potentially relevant results showed matched titles, of which 13 articles met the requirements and were included in the literature review.

**Limitations:** Vague nonspecific clinical manifestations, makes it challenging to establish an early diagnosis and seek an appropriate counseling. In addition, it is difficult to diagnose due to the slow growing behavior and the tumor's benign appearance. As a result of all of that there is no enough cases reported in the literature.

**Conclusion:** This review highlights the need of high index of suspicion to help reach an early and proper diagnosis and to raise awareness. *Dermatofibrosarcoma Protuberans* needs a specialized center in order to identify and recognize the disease. The knowledge and awareness of the disease is low since it is rare.

**Keywords:** *Dermatofibrosarcoma Protuberans*, soft tissue sarcoma, skin cancer, superficial skin lesions, dermatosurgery.

**Search Strategy:**

A systematic review was done of the included articles for this current study from September 13, 2020 to September 22, 2020 using the keywords: “*Dermatofibrosarcoma Protuberans*” and “soft tissue sarcoma”. The data were obtained from a thorough search from two main electronic databases: PubMed and Web of Science yielding 1,769 matched results, where 13 articles were chosen. The disease entity of *Dermatofibrosarcoma Protuberans* was covered thoroughly with a focus of its histopathological findings and new treatment modalities.

**Introduction:**

***Dermatofibrosarcoma Protuberans (DFSP)*** Is a low to intermediate rare superficial soft tissue sarcoma. It is a cutaneous cancer that is derived from the dermis, the middle layer of the skin. *DFSP* was first described back in 1980 by *Taylor*. Followed by establishing *DFSP* as a distinct histopathological entity by *Darier* and *Ferrand* in 1924. In 1925, it was named by *Hoffman* [1]. In fact, it is a type of sarcoma that is known to have low metastatic potential. However, it is characterized to be locally invasive. Since this cancer can invade the deep layers including: subcutaneous tissue, muscles, and even bones; it is documented to have high recurrence rate. The prevalence is more in black ethnic group with a male to female ratio of 1 to1, affecting the younger age groups between the age of 20 to 59 years of age. This tumor most commonly affects the trunk and proximal upper extremities, but it is also reported to arise in other anatomical distribution. It classically occurs in the covered areas not exposed to the sun, in contrast to most of the other types of skin cancers that affects the sun exposed areas. There is no linked disposing factors that are proven until now to cause *DFSP*. There is no significant symptoms the patient can suffer from, the disease takes an indolent course, thus leading the disease going unnoticed. In order to make a diagnosis, a tissue biopsy or an excision is resected and sent to a dermatopathologist using an immunohistochemical tests. Surgical resection by MMS surgery is the mainstay treatment option. Other treatment modalities such as radiotherapy, chemotherapy and tyrosin kinase inhibitors should be considered in cases where we are not able to reach a negative margin or where recurrence of the tumor occur. [2]

**Epidemiology:**

*DFSP* is documented to be more common in black ethnicity, a male to female ratio of 1 to 1, however, some studies suggested a slight male predominance. It classically develops in the 20 to 59 decades of life, with less common incidence affecting pediatric or geriatric age groups. 0.8 to 5 patients per million population are diagnosed each year with *DFSP*. The disease represents 1% of all superficial soft tissue sarcomas [3].

The lesion arises from the second layer of the skin called the dermis. It develops in the non-sun exposed areas where the trunk is the most common site by (42% to 60%) of cases, second location is proximal extremities with the upper limbs accounting for (23% to 25%), followed by lower extremities by (18 %), and finally the head and neck region by (10 to 16%). Having said that, infrequent anatomical distribution have been reported, such as the breasts and genital areas including the vulva and penis [3].

#### **Clinical manifestations and risk factors:**

There are not proven risk factors known until now to cause this soft tissue sarcoma. But it is hypothesized that there is a genetic correlation involved. No family history association have been documented. Certain case reports reported prior chronic injury to the areas where the tumor arises, such as prior trauma, old scar, or immunization in the site of the development of *DFSP*.

Regardless of that, *DFSP* frequently arises on healthy skin in a larger scale of cases.

There are no specific symptoms, however, the lesion gross description is as follows:

*DFSP* is characterized as a painless lesion that starts small in size, flat in shape, pink or violent in color. In addition, the lesion is asymmetric with ill-defined margins, and finger like projections.

lesion. The tumor proliferates slowly over a course of years. As the lesion grows, it has a potential to ulcerate, bleed, and become necrotized. Moreover, it is locally invasive, with a potential to invade up to 0.3-12 cm peripherally and vertically deep into the internal structures reaching the viscera and bones [3]. It is known that the metastasis is rare, but when it occurs, it metastasizes into the lymph nodes and the lungs. Recurrence rate is high and common especially if negative margins were not obtained and the tumor was not completely resected laterally and deeply.

These clinical features justify the difficulty in making a proper diagnosis. Since the lesion is painless and grows very slowly. Also, it appears like an old scar or a benign cyst, the patient will not complain and will not be concerned. As a result, the diagnosis needs high index of suspicion and a specialized center with multidisciplinary team approach [2].

#### **Pathophysiology:**

The early event happens when a new mutation takes place in a healthy cell and gives rise to four main histopathological variants, which are *Myxoid DFSP*, *Bednar Tumors*, *Giant Cell Fibroblastoma*, and lastly *Fibrosarcomatous* (FS) *DFSP*. A translocation of a t(17, 22) gene and a binding of collagen type 1 alpha 1 growth factor genes mainly platelet-derived growth factor subunit b (PDGFB) resulting in activation and stimulation of tyrosin kinase receptors. Once tyrosin kinase receptors are activated, unprogrammed cell proliferation will follow and will lead to the abnormal tumor growth, and from here comes the name "*Protuberans*" which means lump of tissue. Targeted molecular therapy of tyrosin kinase inhibitors have a role in

inhibition of tyrosin kinase receptors and as a result leading to depressive effect on the cell proliferation [1].

### **Histology:**

Histologically, *DFSP* evaluation is challenging given histologic similarities to other fibroblastic soft tissue tumors. *DFSP* microscopic examination will show a spindle cell proliferation in an irregularly whorled or storiform pattern oriented parallel to the skin surface, often surrounding subcutaneous fat to form a honeycomb appearance. Involvement of the fascia, underlying muscles, periosteum and bone is a late event [2]. One of the predominant features of *DFSP* is the ability to penetrate surrounding tissue, with tumor cells invading subcutaneous tissue in the form of irregular finger-like projections through the septa and fat lobules [4]. These tumor extensions contain few cells, and at first glance, it can appear identical to normal fibrous tracts. This makes it hard to determine the exact extent of the tumor and perhaps why recurrences appear after excision with wide margins. [4]. The presence of a sarcomatous changes in *DFSP* is a sign of tumor progression, it increases the tumor grade from low to intermediate, but the effect on prognosis is still debated. Mostly, sarcomatous component suggest worse prognosis and a higher rate of metastases.

### **Immunohistochemical profile:**

The main diagnosis of *DFSP* is usually based on the immunohistochemical and routine histopathological features. Despite this classic pattern, *DFSP* can be challenging to differentiate from other tumors on hematoxylin and eosin staining and might require immunohistochemical

staining [3]. A typical staining profile for *DFSP* includes expression of CD34 which is considered characteristic for the diagnosis of *DFSP*. CD34 often positive in *DFSP* (80%-100% of *DFSP* express this marker) and negative for factor XIIIa (2013). CD34 is one of the most effective stains to differentiate *DFSP* from other soft tissue tumors.

The sensitivity of CD34 Immunohistochemistry in *DFSP* ranges from 84 to 100 percent, whereas between 2.5 and 5 percent of dermatofibromas stain positively. Hence, the reliability of CD34 staining is not accurate [4].

Moreover, a new study suggests utility for Immunohistochemistry staining for CD44 and hyaluronate in the differential diagnosis of *DFSP* and dermatofibroma. *DFSP* tends to be strongly positive for hyaluronate, whereas CD44 is significantly reduced or absent. In contrast, The cells of dermatofibromas tend to stain intensely for CD44, when its stroma stains slightly for hyaluronate [14].

### **Biological Sub-Types:**

There are numerous histologic variants of *DFSP* including *Giant Cell Fibroblastoma* (*GCF*), pigmented, myxoid, atrophic, and *DFSP* with fibrosarcomatous change (*DFSP-FS*) [3]. The primary myxoid variant is characterized as containing more than 50% myxoid stroma.

Histologically, *myxoid DFSP* shows the classic infiltrative growth pattern, honeycomb appearance along with CD34 positivity present in *DFSP*. *Myxoid DFSP* is differentiated by sheetlike, bland spindle cells along with pale stroma and lobular proliferation [11].

The *Bednar tumor* (pigmented variant) accounts for less than 1% of *DFSPs*. It is found most in the pediatric population and African Americans. As with classic *DFSP*, it presents most commonly on the extremities and extremities.

Moreover, *Bednar tumors* are identical to the classic *DFSP*, except for the presence of melanin. Furthermore, the *Bednar tumor* is less aggressive with lower rates of local recurrence. It is crucial to differentiate *Bednar tumors* from other pigmented lesions such as melanoma, because the management and the outcomes are different. [3].

Atrophic or morphea-like *DFSP*, a rare form of *DFSP* has been documented. Atrophic *DFSP* appear like other benign lesions such as idiopathic atrophoderma, morphea, , atrophic scar, anetoderma or lipoatrophy. Mostly, it affects young to middle aged adults. If not fully excised, a high rate of local recurrence will occur. Metastases are rare and generally occur after recurrent local recurrence [5].

#### **DDX:**

The clinical differential diagnosis of *Dermatofibrosarcoma Protuberans (DFSP)* is broad, and can include a number of diseases, depending on the location and size of the tumor. The nodular form of *DFSP* may be clinically confused with *neurofibroma, leiomyoma, epidermal (sebaceous) cyst, malignant melanoma, basal cell carcinoma, keloid, desmoid tumor, dermatofibroma, lipoma, nodular fasciitis, sarcoidosis, and other cutaneous soft tissue sarcomas including Kaposi sarcoma, fibrosarcoma/fibromyxosarcoma, liposarcoma, leiomyosarcoma, angiosarcoma, and undifferentiated/unclassified soft tissue sarcoma.* [12].

### **Management and treatment:**

*Dermatofibrosarcoma protuberans* presents as an asymptomatic, skin-colored to red-brown indurated plaque which may develop to multiple raised violaceous to red-brown nodules. The atrophic variant presents as a violaceous plaque, the tumor sometimes ulcerates and becomes painful.

The majority of *DFSPs* occur on the trunk, followed by the extremities and then head and neck. The shoulder and pelvic region are characteristic areas. The tumor is known to have growth with asymmetric, root-like projections which cannot be appreciated on clinical exam. Thus, local recurrence following excision is common. Distant metastasis is rare, the lung is the most common site of metastasis [6].

The treatment of *DFSP* often requires a multidisciplinary approach. Depending on location, dermatologic surgeons, surgical oncologists, head and neck surgeons, neurosurgeons, plastic surgeons, and medical oncologists

*Mohs micrographic surgery (MMS)* is the preferred method when available, most of the *DFSP* cases are often advanced cases; thus, dermatologic surgeons obtain clear margins peripherally and other surgical specialties assist with resection of the fascia and any critical deeper structures. When *MMS* is not available, wide local excision (at least 2- to 3-cm margins of resection) with pathologic assessment of margin status is recommended [13].

*WLE* was the most common surgical modality used to treat *DFSP* across the UK. Local recurrence rate was very low, occurring only after *WLE* [7].

for the treatment of *DFSP* that is unresectable, recurrent, or metastatic give

*Imatinib* Mesylate. *Imatinib* is an antineoplastic agent, a class of medication that is classified as selective tyrosine kinase antagonist. The mechanism of action is by inhibiting tyrosine kinase receptors for platelet derived growth factor. This medication signals apoptosis of cancerous cells that overexpress oncoproteins and suppresses their unprogrammed and rapid multiplication [15]. It is a tyrosine kinase inhibitor approved by the *US Food and Drug Administration* in 2006 , *Imatinib* inhibits the kinase activity of platelet derived growth factor receptor and is taken as 400 mg by mouth once or twice daily. It works for *DFSP* with t(17;22) with a 50% response rate. In some cases of unresectable *DFSP* or *DFSP* that would require mutilating surgery, treatment with *imatinib* has helped reduce the tumor burden to allow for resection and complete remission. *Imatinib* does not eradicate metastatic *DFSP* and there is a strong likelihood that metastatic [8]. The main treatment of *Dermatofibrosarcoma Protuberance* is surgical. However, the initial and a crucial step of treatment is to shrink the tumor size prior to the surgery. Medical treatment with *Imatinib* is the first line treatment and should be initiated to halt the rate of tumor growth [20]. Administration of *Imatinib* results in improvement of the local mass effect of the tumor in addition to reduction of the invasive nature of *Dermatofibrosarcoma Protuberans* [18]. Clinically, weighing potential benefits against risks, *Imatinib* side effects are tolerable in relation to its benefits. List of the most common *Imatinib* side effects:

- Nausea/vomiting
- Fever
- Headache
- Myalgia
- Thrombocytopenia
- Anemia

- Generalized body edema
- Diarrhea
- Skin rash

Moreover, it has been shown that radiotherapy may improve local control and reduce the risk of recurrence postoperatively in patients with *DFSP* [9].

### **Prognosis:**

The overall prognosis of *Dermatofibrosarcoma Protuberans* is good, with a 10-year survival rate of 99.1%. As metastasis is rare, morbidity due to local recurrence is a more common issue. Age older than 50 is a risk factor for local recurrence. Patients with metastatic disease live on average about 2 years after the time of diagnosis. A high mitotic index, increased cellularity, black race, male sex, and location on the head, neck, or limb are risk factors for higher mortality rates [14].

### **Discussion:**

*Dermatofibrosarcoma Protuberans* (*DFSP*) is a rare soft tissue sarcoma, is derived from the dermis and have low metastatic potential [15]. However it is locally invasive, There is no linked disposing factors that are proven until now to cause *DFSP*, But it is hypothesized that there is a genetic correlation. There is no significant symptoms and takes an indolent course thus leading the disease going unnoticed [16]. The tumor proliferates slowly over a course of years and painless lesions, small in size These clinical features justify the difficulty in making a proper

diagnosis [17]. Tissue biopsy is done with using an immunohistochemical tests to make diagnosis, DFSP evaluation is challenging given histologic similarities to other fibroblastic soft tissue tumors. microscopic examination will show a spindle cell proliferation in an irregularly whorled or storiform pattern (1 e). CD34 is one of the most effective stains to differentiate DFSP from other soft tissue tumors, Moreover, a new study suggests utility for Immunohistochemistry staining for CD44 and hyaluronate in the differential diagnosis of *DFSP* and dermatofibroma. *DFSP* tends to be strongly positive for hyaluronate, In contrast, The cells of dermatofibromas tend to stain intensely for CD4 [4]. The treatment of *DFSP* often requires a multidisciplinary approach, surgical resection by *MMS* surgery is the mainstay treatment option thus, dermatologic surgeons obtain clear margins peripherally, another surgical option is wide local excision (at least 2- to 3-cm margins of resection) [1], local recurrence rate was very low, occurring only after WLE(3n). 1

Other treatment modalities such as radiotherapy, chemotherapy and tyrosin kinase inhibitors (*Imatinib mesylate*) should be considered in cases where we are not able to reach a negative margin or where recurrence of the tumor occur [19]. The overall prognosis of *Dermatofibrosarcoma Protuberans* is good, with a 10-year survival rate of 99.1%.(1n) [6].

### **Conclusion:**

*Dermatofibrosarcoma protuberans (DFSP)* is a rare malignant mesenchymal tumor that originate in the dermis and is characterized by latency in its initial detection. Even though *DFSP*

has a low metastatic potential, there is high chance of local recurrence with repeated excisions.

Mostly, it affects proximal extremities and trunk particularly areas not exposed to the sun [2].

*DFSP* represent 1% of all soft tissue sarcomas [3]. *DFSP* is a result of unprogrammed cell proliferation in which t(17,22) gene translocation occur which will lead to the tumor growth.

*DFSP* is classically diagnosed by IHC and histopathology [3]. The clinical differential diagnosis of *DFSP* is wide, it can be confused with nodular fasciitis, lipoma, desmoid tumor, basal cell carcinoma, keloid and leiomyoma.

*DFSP* management requires a multidisciplinary approach with Mohs micrographic surgery being the best since most of *DFSP* cases are diagnosed in advanced stages. *DFSP* overall prognosis is good.

**Financial support and sponsorship:**

Nil.

**Conflict of interest:**

There is no conflict of interest.

**REFERENCES:**

- [1] Acosta AE, Vélez CS. Dermatofibrosarcoma Protuberans. *Curr Treat Options Oncol.* 2017;18(9):56. Published 2017 Aug 10. doi:10.1007/s11864-017-0498-5

[2] Allen A, Ahn C,  
Sangüeza OP.

Dermatofibrosarcoma Protuberans. *Dermatol Clin.* 2019;37(4):483-488.

doi:10.1016/j.det.2019.05.006

[3] Reha J, Katz SC. Dermatofibrosarcoma Protuberans. *Surg Clin North Am.* 2016;96(5):1031-1046. doi:10.1016/j.suc.2016.05.006

[4] Mendenhall W, Scarborough M, Flowers F. Dermatofibrosarcoma protuberans: Epidemiology, pathogenesis, clinical presentation, diagnosis, and staging. Uptodate. 2019

[5] Bakry O, Attia A. Atrophic dermatofibrosarcoma protuberans. *J Dermatol Case Rep.* 2012;6(1):14-17. doi:10.3315/jdcr.2012.1089

[6] Stamatakos M, Fyllos A, Siafogianni A, Ntzeros K, Tasiopoulou G, Rozis M, Kontzoglou K. Dermatofibrosarcoma protuberans: a rare entity and review of the literature. *J BUON.* 2014 Jan-Mar;19(1):34-41. PMID: 24659640.

[7] Durack A, Gran S, Gardiner MD, et al. A 10-year review of surgical management of dermatofibrosarcoma protuberans. 2020 Jun 29]. *Br J Dermatol.* 2020;10.1111/bjd.19346. doi:10.1111/bjd.19346

- [8] Cheraghi, N., Shulman, K., & Khorasani, H. . Management of Dermatofibrosarcoma Protuberans. *Recent Advances in Skin Cancer*. 2017.
- [9] Al Barwani AS, Taif S, Al Mazrouai RA, Al Muzahmi KS, Alrawi A. Dermatofibrosarcoma Protuberans: Insights into a Rare Soft Tissue Tumor. *J Clin Imaging Sci*. 2016;6:16. 2016 Apr 29. doi:10.4103/2156-7514.181492
- [10] Llombart B, Serra C, Requena C, Alsina M, Morgado-Carrasco D, Través V, Sanmartín O. Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans. *Actas Dermosifiliogr (Engl Ed)*. 2018 Dec;109(10):868-877. English, Spanish. doi: 10.1016/j.ad.2018.05.006. Epub 2018 Jul 4. PMID: 30539729.
- [11] Thway K, Noujaim J, Jones RL, Fisher C. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. *Ann Diagn Pathol*. 2016 Dec;25:64-71. doi: 10.1016/j.anndiagpath.2016.09.013. Epub 2016 Sep 27. PMID: 27806849.
- [12] Penel N, El Bedoui S, Robin YM, Decanter G. Dermatofibrosarcome : prise en charge [Dermatofibrosarcoma: Management]. *Bull Cancer*. 2018 Nov;105(11):1094-1101. French. doi: 10.1016/j.bulcan.2018.08.008. Epub 2018 Oct 5. PMID: 30297237.

- [13] Mujtaba B, Wang F, Taher A, Aslam R, Madewell JE, Spear R, Nassar S. Dermatofibrosarcoma Protuberans: Pathological and Imaging Review. *Curr Probl Diagn Radiol*. 2021 Mar-Apr;50(2):236-240. doi: 10.1067/j.cpradiol.2020.05.011. Epub 2020 Jun 1. PMID: 32620358.
- [14] Grizzetti L, Gaide O, Kuonen F. Dermatofibrosarcoma protuberans : aspects clinico-pathologiques et prise en charge [Dermatofibrosarcoma protuberans : clinico-pathological aspects and management]. *Rev Med Suisse*. 2020 Apr 1;16(688):640-645. French. PMID: 32239838.
- [15] Han A, Chen EH, Niedt G, Sherman W, Ratner D. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. *Arch Dermatol*. 2009 Jul;145(7):792-6. doi: 10.1001/archdermatol.2009.140. PMID: 19620561.
- [16] Ramirez-Fort MK, Meier-Schiesser B, Niaz MJ, Niaz MO, Feily A, Fort M, Lange CS, Caba D. Dermatofibrosarcoma Protuberans: The Current State of Multidisciplinary Management. *Skinmed*. 2020 Oct 1;18(5):288-293. PMID: 33160438.
- [17] Breuninger H, Sebastian G, Garbe C. Dermatofibrosarcoma protuberans--an update. *J Dtsch Dermatol Ges*. 2004 Aug;2(8):661-7. doi: 10.1046/j.1439-0353.2004.04056.x. PMID: 16279228.
- [18] Handolias D, McArthur GA. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. *Future Oncol*. 2008 Apr;4(2):211-7. doi: 10.2217/14796694.4.2.211. PMID: 18407734.

[19] Badhey AK, Tikhtman R, Tang AL. Management of dermatofibrosarcoma protuberans.

Curr Opin Otolaryngol Head Neck Surg. 2021 Aug 1;29(4):278-282. doi:

10.1097/MOO.0000000000000721. PMID: 33993132.

[20] Ugurel S. Targeted Therapie des Dermatofibrosarkoms mit Imatinib [Targeted therapy of dermatofibrosarcoma with imatinib]. J Dtsch Dermatol Ges. 2007 Mar;5(3):261. German. doi:

10.1111/j.1610-0387.2007.07009.x. PMID: 17338806.

UNDER PEER REVIEW